Extension of COVID-19 Telemedicine Flexibilities
May 12, 2023
Effective today, the United States Drug Enforcement Administration (DEA) extended the full set of telemedicine flexibilities adopted during the COVID-19 public health emergency for six months – through November 11, 2023. For any practitioner-patient telemedicine relationships that have been or will be established up to November 11, 2023, the full set of telemedicine flexibilities regarding prescription of controlled medications established during the COVID-19 PHE will be extended for one year – through November 11, 2024. OMH is in the process of updating guidance for providers regarding this new temporary rule.
The DEA press release and text of the temporary rule extending the flexibilities are available at: